https://doi.org/10.55788/ab991879
Dr Nelsan Pourhadi (Copenhagen University Hospital Rigshospitalet, Denmark) and colleagues investigated data from 1,872,854 individuals between 60–75 years of age in the year 2000, or turning 60 between 2000 and 2020, to assess the link between opioid use and the risk for dementia [1]. Individuals with cancer, established dementia, or previous opioid use or addiction were not included in the study.
In total, 93,638 cases of all-cause dementia were identified. Incidence-density-matching per sex and age was conducted using 468,190 controls. The investigators applied a total standardised dose (TSD) to compare the quantity of opioids that was taken by an individual. One TSD was equivalent to 30 mg of oral morphine per day. Also, the authors used a default 5-year lag time window between the last opioid intake and the diagnosis of dementia to reduce reverse causation bias.
“There was an association between opioid use and dementia,” said Dr Pourhadi. “But this association only appeared to exist if a patient had used 90 TSDs or more.” For individuals between 60–75 years of age who had used between 31–90 TSDs, the incidence rate ratio (IRR) was 1.06 (95% CI 0.99–1.13). In the same age category, the IRRs for individuals who had used between 91–200 TSDs, between 201–500 TSDs, and over 500 TSDs were 1.28 (95% CI 1.16–1.41), 1.44 (95% CI 1.28–1.62), and 1.58 (95% CI 1.43–1.75), respectively. This trend was consistent across age categories, except for the 90+ category, in which the authors did not find an association between opioid use and the risk for dementia. Furthermore, the effect was consistent irrespective of ‘weak’ or ‘strong’ opioid use but appeared to be less pronounced in the chronic-pain subgroup of patients.
“Following these findings, it would be interesting to investigate the link between opioid use and dementia in dementia subtypes and to examine the potential causality of the observed associations,” Dr Pourhadi concluded.
- Pourhadi N, et al. Opioids and the risk of dementia. Late-breaking session 1, 10th EAN Congress, 29 June–2 July 2024, Helsinki, Finland.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Novel tool to predict outcomes in anti-NMDAR encephalitis Next Article
Therapeutic advancement in Pompe disease »
« Novel tool to predict outcomes in anti-NMDAR encephalitis Next Article
Therapeutic advancement in Pompe disease »
Table of Contents: EAN 2024
Featured articles
Extended success for N-acetyl-L-leucine in Niemann-Pick disease type C
Treatment escalation and de-escalation in late-onset MS
Diagnostics and Disease Management in Neurology
What is the value of transcranial ultrasound for diagnosing Parkinson’s disease?
How to achieve goal-concordant care in severe acute brain injury?
Changing treatment landscape in myasthenia gravis
Stroke and Vascular Events
High risk for recurrent vascular events in young stroke patients
Anticoagulation or antiplatelet as secondary prevention for cancer-related strokes?
Multiple Sclerosis
Treatment escalation and de-escalation in late-onset MS
How different are late onset and adult onset MS really?
Advances in Neurostimulation
Vagal nerve stimulation for the reduction of cognitive impairment in Alzheimer’s disease
Spinal cord stimulation for chronic pain: state-of-affairs in 2024
Innovations in VNS and DBS for refractory epilepsy
Genetic and Molecular Therapies
Extended success for N-acetyl-L-leucine in Niemann-Pick disease type C
Therapeutic advancement in spinal muscular atrophy
Therapeutic advancement in Pompe disease
Neurological Risk Factors and Predictive Tools
Under investigation: Opioid use and the risk for dementia
Novel tool to predict outcomes in anti-NMDAR encephalitis
Related Articles
December 28, 2020
Brain stimulation may help improve emotional regulation
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com